Replies to post #113189 on Biotech Values

[HattieTheWitch]

See subsequent posts, but it was the immunogenicity data, which, according to the FDA, was requested to assess the manufacturing process wrt impurities. We know that was not a "minor" slowdown, timewise.

Thank you very much. If you know, how did MNTA overcome FDA's concerns?

The more I read as the day goes on, things keep coming back to two things that have been issues for quite a while: 1) TEVA's unwillingness to speak the plain truth, and 2) questions about TEVA's ability to do what MNTA has done without MNTA's IP.

Because of this, I'm more and more convinced that this price drop is a gross overreaction, and so am buying back my covered calls. (Until I sell them again, Dew should be VERY happy!)